News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

National Comprehensive Cancer Network Receives $2 Million in Oncology Research Funding from Boehringer Ingelheim Corporation to Investigate Afatinib in Solid Tumors


11/10/2011 8:38:39 AM

FORT WASHINGTON, Pa.--(BUSINESS WIRE)--The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has been awarded a $2 million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to develop a program to scientifically evaluate and define the clinical effectiveness of Afatinib (BIBW 2992) in solid tumors, including breast, head and neck, and non-small cell lung (NSCL) cancers.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES